Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced positive topline results from the pioneering TOGETHER-PsA Phase 3b trial.

Richmond, VA, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Kaléo, a global leader in drug-delivery device technology and auto-injectors, today announced the appointment of Ram Halthore as Vice President, ...

Findings showed 31.7% of patients receiving ixekizumab and tirzepatide achieved both ACR50 and at least 10% weight loss vs 0.8% on ixekizumab monotherapy. Topline data were announced from a phase 3b ...

On Thursday, Eli Lilly and Co. (NYSE: LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide ...

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to =10% weight reduction with concomitant Taltz and ...

Jan 8 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis ...

As evidence of tirzepatide’s efficacy mounts across a range of cardiometabolic conditions, Eli Lilly has shown that taking the incretin medicine alongside another of its drugs, Taltz, could lead to ...

As part of the back-to-school rush, GoodRx, a platform for medication savings, reports the demand for epinephrine (EpiPen, EpiPen Jr, Adrenaclick, Auvi-Q) auto-injectors tends to spike in the summer ...

Elaine Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech. Elaine Chen covers biotech, co-writes The Readout ...

The ILUMYA Pen offers eligible patients a safe and effective treatment option that supports ease of use and may help reduce clinical visits through self-administration MUMBAI, India and BRAMPTON, ON, ...